Navrogen Inc. has entered into a cooperative research and development agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate (ADC) NAV-001, under supervision of the NCI.
Affimed NV and Artiva Biotherapeutics Inc. have entered into a new strategic partnership to jointly develop, manufacture and commercialize a combination therapy comprised of Affimed's Innate Cell Engager (ICE) AFM-13 and Artiva's cord blood-derived, cryopreserved off-the-shelf allogeneic natural killer (NK) cell product candidate, AB-101.
Exelixis Inc. and Sairopa BV have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.
Regeneron Pharmaceuticals Inc. has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with Abcellera Biologics Inc. as part of a multitarget collaboration between the companies, into further preclinical development.
Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.
Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.
RSS
